Aprepitant for nausea from chemotherapy
Canadian Coordinating Office for Health Technology Assessment
Record ID 32003001143
English, French
Authors' objectives:
To summarize the available evidence on the use of aprepitant for the treatment of acute and delayed nausea due to highly emetogenic chemotherapy.
Authors' recommendations:
Aprepitant seems to offer a significant advantage for treating vomiting when used with standard therapy (i.e., dexamethasone and a 5-HT3 antagonist). The larger clinical trials, however, failed to show a statistically significant improvement with aprepitant when only nausea was evaluated. The FDA reviewer raised concern about the definition of highly emetogenic doses of cisplatin being equal to or greater than 70 mg/m2. In the ondansetron submission, the highly emetogenic dose of cisplatin was between 100 and 120 mg/m2. Whether the significant reduction in vomiting observed with aprepitant in these studies would be maintained at higher doses of cisplatin is yet to be proven. More research with higher cisplatin doses would be useful in determining aprepitant's place following highly emetogenic chemotherapy.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antiemetics
- Costs and Cost Analysis
- Drug Therapy
- Nausea
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.